Webinar video | Life Sciences Session #3: ‘Trop is te veel’: what not to do in case of pricing of medicines?
The COVID-19 pandemic challenges companies and firms worldwide, and requires us all to adopt new proactive approaches. While COVID-19 prevents us from being together, our Life Sciences team takes the initiative to give you short, digestible and regular online Life Sciences Sessions.
Are you trying to see the wood for the trees when setting prices and arranging reimbursement for you medicines in Belgium? Is “the sky the limit” for your medicines’ prices? Or are you also wondering what all the fuzz is about the Commission’s decision towards Aspen?
- Kirian Claeyé will guide you through the regulatory maze of pricing and reimbursement of medicines in Belgium.
- Beatrijs Gielen and Nina Methens will clarify the European Courts’ approach towards excessive pricing under competition law, in particular in the pharma sector, and will discuss the long-awaited European Commission settlement decision in the Aspen case.
Recommended articles
New EU sample retention rules coming up for veterinary medicines repackaged for parallel trade
The Veterinary Medicinal Products Regulation (EU) 2019/6 has applied in the EU since 28 January 2022, replacing Directive 2001/82/EC. The new rules on good manufacturing practice (GMP) will in turn be fleshed out by Commission Implementing Regulation (EU) 2025/2091, which will apply from 16 July 2026. In addition, the European Commission is introducing new GMP requirements concerning the retention of samples for veterinary medicinal products that are repackaged for parallel trade. This blog post briefly examines what these new obligations entail.
Read on
EU General Court bars patient association from challenging medicine authorisation refusal
In Case T‑278/25, the EU General Court recently dismissed as inadmissible a challenge brought by a patient advocacy association against the European Commission’s refusal to renew the conditional marketing authorisation for a treatment against Duchenne muscular dystrophy (DMD). The case is significant because it adds to the case law on contesting Commission decisions relating to the marketing of medicinal products. In this blog post, we look at how the Court came to the conclusion that the association lacked standing to litigate and use this as a basis for an informal categorisation of the existing case law.
Read on
Despite EU harmonisation, Member States may impose authorisation requirements on pharmacy-prepared medicines, rules EU Court of Justice
Under EU pharmaceutical law, certain medicines fall outside the scope of Directive 2001/83/EC (i.e. the Community code on medicinal products for human use). This includes “magistral formulae” (prepared in a pharmacy for an individual patient on prescription) and “officinal formulae” (prepared in a pharmacy in accordance with a pharmacopoeia and supplied directly to that pharmacy’s […]
Read on